|
1
|
Tsang KY, Zaremba S, Nieroda CA, Zhu MZ,
Hamilton JM and Schlom J: Generation of human cytotoxic T cells
specific for human carcinoembryonic antigen epitopes from patients
immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer
Inst. 87:982–990. 1995. View Article : Google Scholar
|
|
2
|
Palermo B, Del Bello D, Sottini A, et al:
Dacarbazine treatment before peptide vaccination enlarges T-cell
repertoire diversity of melan-a-specific, tumor-reactive CTL in
melanoma patients. Cancer Res. 70:7084–7092. 2010. View Article : Google Scholar
|
|
3
|
Toes RE, Blom RJ, van der Voort E,
Offringa R, Melief CJ and Kast WM: Protective antitumor immunity
induced by immunization with completely allogeneic tumor cells.
Cancer Res. 56:3782–3787. 1996.PubMed/NCBI
|
|
4
|
Meng F, Song H, Luo C, et al: Correlation
of LAPTM4B polymorphisms with cervical carcinoma. Cancer.
117:2652–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao M, Jia S, Wang H, Wang J, Huang Y and
Li Z: Overexpression of LAPTM4B: an independent prognostic marker
in breast cancer. J Cancer Res Clin Oncol. 139:661–667. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meng F, Li H, Zhou R, Luo C, Hu Y and Lou
G: LAPTM4B gene polymorphism and endometrial carcinoma risk and
prognosis. Biomarkers. 18:136–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Y, Liu Y, Zhou R, et al: LAPTM4B
polymorphisms is associated with ovarian cancer susceptibility and
its prognosis. Jpn J Clin Oncol. 42:413–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shao GZ, Zhou RL, Zhang QY, et al:
Molecular cloning and characterization of LAPTM4B, a novel gene
upregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu XS, Dyer J, Leggatt GR, et al:
Overcoming original antigenic sin to generate new CD8 T cell
IFN-gamma responses in an antigen-experienced host. J Immunol.
177:2873–2879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang H, Zhai G, Ji X, Xiong F, Su J and
McNutt MA: LAPTM4B allele *2 is a marker of poor prognosis
following hepatic tumor resection for hepatocellular carcinoma.
PLoS One. 7:e349842012.
|
|
11
|
Zhai G, Yan K, Ji X, et al: LAPTM4B allele
*2 is a marker of poor prognosis for gallbladder carcinoma. PLoS
One. 7:e452902012.
|
|
12
|
Zhou L, He XD, Chen J, et al:
Overexpression of LAPTM4B-35 closely correlated with
clinicopathological features and post-resectional survival of
gallbladder carcinoma. Eur J Cancer. 43:809–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kirk CJ, Hartigan-O’Connor D, Nickoloff
BJ, et al: T cell-dependent antitumor immunity mediated by
secondary lymphoid tissue chemokine: augmentation of dendritic
cell-based immunotherapy. Cancer Res. 61:2062–2070. 2001.PubMed/NCBI
|
|
14
|
Wang W, Epler J, Salazar LG and Riddell
SR: Recognition of breast cancer cells by CD8+ cytotoxic T-cell
clones specific for NY-BR-1. Cancer Res. 66:6826–6833. 2006.
|
|
15
|
Parker KC, Bednarek MA and Coligan JE:
Scheme for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J Immunol.
152:163–175. 1994.PubMed/NCBI
|
|
16
|
Gatz SA, Pohla H and Schendel DJ: A
PCR-SSP method to specifically select HLA-A*0201 individuals for
immunotherapeutic studies. Tissue Antigens. 55:532–547.
2000.PubMed/NCBI
|
|
17
|
Neumann F, Wagner C, Preuss KD, et al:
Identification of an epitope derived from the cancer testis antigen
HOM-TES-14/SCP1 and presented by dendritic cells to circulating
CD4+ T cells. Blood. 106:3105–3113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neumann F, Wagner C, Stevanovic S, et al:
Identification of an HLA-DR-restricted peptide epitope with a
promiscuous binding pattern derived from the cancer testis antigen
HOM-MEL-40/SSX2. Int J Cancer. 112:661–668. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nolte A, Scheffold C, Slotty J, et al:
Generation of melanoma-specific cytotoxic T lymphocytes for
allogeneic immunotherapy. J Immunother. 26:257–269. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boon T: Tumor antigens recognized by
cytolytic T lymphocytes: present perspectives for specific
immunotherapy. Int J Cancer. 54:177–180. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rammensee H, Bachmann J, Emmerich NP,
Bachor OA and Stevanovic S: SYFPEITHI: database for MHC ligands and
peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barnea E, Beer I, Patoka R, et al:
Analysis of endogenous peptides bound by soluble MHC class I
molecules: a novel approach for identifying tumor-specific
antigens. Eur J Immunol. 32:213–222. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ramakrishna V, Ross MM, Petersson M, et
al: Naturally occurring peptides associated with HLA-A2 in ovarian
cancer cell lines identified by mass spectrometry are targets of
HLA-A2-restricted cytotoxic T cells. Int Immunol. 15:751–763. 2003.
View Article : Google Scholar
|
|
24
|
Fairchild PJ and Wraith DC: Lowering the
tone: mechanisms of immunodominance among epitopes with low
affinity for MHC. Immunol Today. 17:80–85. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shastri N, Schwab S and Serwold T:
Producing nature’s gene-chips: the generation of peptides for
display by MHC class I molecules. Annu Rev Immunol. 20:463–493.
2002.
|
|
26
|
Ren XB, Yu JP, Cao S, et al: Antitumor
effect of large doses IL-2-activated HLA haploidentical peripheral
blood stem cells on refractory metastatic solid tumor treatment.
Cancer Biother Radiopharm. 22:223–234. 2007. View Article : Google Scholar
|
|
27
|
Smyth MJ, Godfrey DI and Trapani JA: A
fresh look at tumor immunosurveillance and immunotherapy. Nat
Immunol. 2:293–299. 2001. View
Article : Google Scholar : PubMed/NCBI
|
